2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors

L. Stewart Massad, Mark H. Einstein, Warner K. Huh, Hormuzd A. Katki, Walter K. Kinney, Mark Schiffman, Diane Solomon, Nicolas Wentzensen, Herschel W. Lawson

Research output: Contribution to journalArticle

425 Citations (Scopus)

Abstract

A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14-15, 2012, to revise the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines. The group's goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) following adoption of cervical cancer screening guidelines incorporating longer screening intervals and co-testing. In addition to literature review, data from almost 1.4 million women in the Kaiser Permanente Northern California Medical Care Plan provided evidence on risk after abnormal tests. Where data were available, guidelines prescribed similar management for women with similar risks for CIN 3, AIS, and cancer. Most prior guidelines were reaffirmed. Examples of updates include: Human papillomavirus-negative atypical squamous cells of undetermined significance results are followed with co-testing at 3 years before return to routine screening and are not sufficient for exiting women from screening at age 65 years; women aged 21-24 years need less invasive management, especially for minor abnormalities; postcolposcopy management strategies incorporate co-testing; endocervical sampling reported as CIN 1 should be managed as CIN 1; unsatisfactory cytology should be repeated in most circumstances, even when HPV results from co-testing are known, while most cases of negative cytology with absent or insufficient endocervical cells or transformation zone component can be managed without intensive follow-up.

Original languageEnglish (US)
JournalJournal of Lower Genital Tract Disease
Volume17
Issue number5 SUPPL.1
DOIs
StatePublished - Apr 2013

Fingerprint

Early Detection of Cancer
Cervical Intraepithelial Neoplasia
Uterine Cervical Neoplasms
Guidelines
Neoplasms
Cell Biology
Colposcopy
Organizations
Pathology
Health
Adenocarcinoma in Situ

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. / Massad, L. Stewart; Einstein, Mark H.; Huh, Warner K.; Katki, Hormuzd A.; Kinney, Walter K.; Schiffman, Mark; Solomon, Diane; Wentzensen, Nicolas; Lawson, Herschel W.

In: Journal of Lower Genital Tract Disease, Vol. 17, No. 5 SUPPL.1, 04.2013.

Research output: Contribution to journalArticle

Massad, LS, Einstein, MH, Huh, WK, Katki, HA, Kinney, WK, Schiffman, M, Solomon, D, Wentzensen, N & Lawson, HW 2013, '2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors', Journal of Lower Genital Tract Disease, vol. 17, no. 5 SUPPL.1. https://doi.org/10.1097/LGT.0b013e318287d329
Massad, L. Stewart ; Einstein, Mark H. ; Huh, Warner K. ; Katki, Hormuzd A. ; Kinney, Walter K. ; Schiffman, Mark ; Solomon, Diane ; Wentzensen, Nicolas ; Lawson, Herschel W. / 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. In: Journal of Lower Genital Tract Disease. 2013 ; Vol. 17, No. 5 SUPPL.1.
@article{990a5fce211c475dae242371e4770739,
title = "2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors",
abstract = "A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14-15, 2012, to revise the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines. The group's goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) following adoption of cervical cancer screening guidelines incorporating longer screening intervals and co-testing. In addition to literature review, data from almost 1.4 million women in the Kaiser Permanente Northern California Medical Care Plan provided evidence on risk after abnormal tests. Where data were available, guidelines prescribed similar management for women with similar risks for CIN 3, AIS, and cancer. Most prior guidelines were reaffirmed. Examples of updates include: Human papillomavirus-negative atypical squamous cells of undetermined significance results are followed with co-testing at 3 years before return to routine screening and are not sufficient for exiting women from screening at age 65 years; women aged 21-24 years need less invasive management, especially for minor abnormalities; postcolposcopy management strategies incorporate co-testing; endocervical sampling reported as CIN 1 should be managed as CIN 1; unsatisfactory cytology should be repeated in most circumstances, even when HPV results from co-testing are known, while most cases of negative cytology with absent or insufficient endocervical cells or transformation zone component can be managed without intensive follow-up.",
author = "Massad, {L. Stewart} and Einstein, {Mark H.} and Huh, {Warner K.} and Katki, {Hormuzd A.} and Kinney, {Walter K.} and Mark Schiffman and Diane Solomon and Nicolas Wentzensen and Lawson, {Herschel W.}",
year = "2013",
month = "4",
doi = "10.1097/LGT.0b013e318287d329",
language = "English (US)",
volume = "17",
journal = "Journal of Lower Genital Tract Disease",
issn = "1089-2591",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL.1",

}

TY - JOUR

T1 - 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors

AU - Massad, L. Stewart

AU - Einstein, Mark H.

AU - Huh, Warner K.

AU - Katki, Hormuzd A.

AU - Kinney, Walter K.

AU - Schiffman, Mark

AU - Solomon, Diane

AU - Wentzensen, Nicolas

AU - Lawson, Herschel W.

PY - 2013/4

Y1 - 2013/4

N2 - A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14-15, 2012, to revise the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines. The group's goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) following adoption of cervical cancer screening guidelines incorporating longer screening intervals and co-testing. In addition to literature review, data from almost 1.4 million women in the Kaiser Permanente Northern California Medical Care Plan provided evidence on risk after abnormal tests. Where data were available, guidelines prescribed similar management for women with similar risks for CIN 3, AIS, and cancer. Most prior guidelines were reaffirmed. Examples of updates include: Human papillomavirus-negative atypical squamous cells of undetermined significance results are followed with co-testing at 3 years before return to routine screening and are not sufficient for exiting women from screening at age 65 years; women aged 21-24 years need less invasive management, especially for minor abnormalities; postcolposcopy management strategies incorporate co-testing; endocervical sampling reported as CIN 1 should be managed as CIN 1; unsatisfactory cytology should be repeated in most circumstances, even when HPV results from co-testing are known, while most cases of negative cytology with absent or insufficient endocervical cells or transformation zone component can be managed without intensive follow-up.

AB - A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14-15, 2012, to revise the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines. The group's goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) following adoption of cervical cancer screening guidelines incorporating longer screening intervals and co-testing. In addition to literature review, data from almost 1.4 million women in the Kaiser Permanente Northern California Medical Care Plan provided evidence on risk after abnormal tests. Where data were available, guidelines prescribed similar management for women with similar risks for CIN 3, AIS, and cancer. Most prior guidelines were reaffirmed. Examples of updates include: Human papillomavirus-negative atypical squamous cells of undetermined significance results are followed with co-testing at 3 years before return to routine screening and are not sufficient for exiting women from screening at age 65 years; women aged 21-24 years need less invasive management, especially for minor abnormalities; postcolposcopy management strategies incorporate co-testing; endocervical sampling reported as CIN 1 should be managed as CIN 1; unsatisfactory cytology should be repeated in most circumstances, even when HPV results from co-testing are known, while most cases of negative cytology with absent or insufficient endocervical cells or transformation zone component can be managed without intensive follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84876149435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876149435&partnerID=8YFLogxK

U2 - 10.1097/LGT.0b013e318287d329

DO - 10.1097/LGT.0b013e318287d329

M3 - Article

VL - 17

JO - Journal of Lower Genital Tract Disease

JF - Journal of Lower Genital Tract Disease

SN - 1089-2591

IS - 5 SUPPL.1

ER -